A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Chen, Jen‐Shi; Chen, Yen‐Yang; Huang, Jian-Jia; Yeh, Kun‐Yun; Chen, Ping‐Tsung; Shen, Wen‐Chi; Hsu, Hung‐Chih; Lin, Yung-Chung; Wang, Hung‐Ming

doi:10.1007/s10120-011-0060-2

Cited by 5 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no standard chemotherapy regimen for advanced gastric cancer. Studies [ 21 – 24 ] have revealed that different chemotherapy regimens have similar efficacies for advanced gastric cancer, but these efficacies were all unsatisfactory. Present literatures have revealed that combined chemoradiotherapy could improve efficacy.…”

Section: Discussionmentioning

confidence: 99%

A clinical analysis of systemic chemotherapy combined with radiotherapy for advanced gastric cancer

Dong¹,

Wang²,

Wang³

et al. 2018

Medicine

View full text Add to dashboard Cite

This study aims to investigate the clinical efficacy of systemic chemotherapy combined with radiotherapy for advanced gastric cancer.A total of 194 advanced gastric cancer patients who were treated from 2006 to 2016 were included in this study. These patients were divided into 2 groups: chemotherapy group (n = 92) and combined chemoradiotherapy group (n = 102). The clinical efficacy of these 2 groups was compared and analyzed to explore the advantageous population and duration of radiotherapy.The remission rates in the chemotherapy group and combined chemoradiotherapy group were 73.5% and 90.6%, respectively, and median survival time was 6.7 versus 10.6 months. Furthermore, the 6-month, 1-year, and 2-year survival rates were 62% versus 83.3%, 22.8% versus 38.2%, and 7.6% versus 13.7%, respectively. All the differences were statistically significant (P < .05). In patients with distant lymph node metastasis, local advanced cancer and organ metastasis, who underwent chemotherapy + radiotherapy, the median survival time was 12.6, 11.1, and 9.8 months, respectively; and the differences were statistically significant compared with the chemotherapy group (P < .05). The median survival time in patients who received concurrent chemoradiotherapy and sequential chemoradiotherapy was 11 and 9.5 months, respectively, and the difference was not statistically significant (P > .05).Combined chemoradiotherapy significantly improved the clinical remission rate, median survival time, and the 6-month, 1-year, and 2-year survival rates in patients with advanced gastric cancer. Furthermore, the survival rate of patients with simple distant lymph node metastasis was better. Concurrent chemoradiotherapy did not significantly improve survival rate compared with sequential chemoradiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A clinical analysis of systemic chemotherapy combined with radiotherapy for advanced gastric cancer

Dong¹,

Wang²,

Wang³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02

Choi

Kim

et al. 2012

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer

Yao

Guo

Yuan

et al. 2013

Journal of Chemotherapy

View full text Add to dashboard Cite

The purpose of this retrospective study was to evaluate the safety and efficacy of docetaxel, oxaliplatin plus fluorouracil (DOF) regimen in comparison with epirubicin, cisplatin and fluorouracil (ECF) regimen in treating AGC. A total of 88 AGC patients were treated with DOF regimen (N = 45) and ECF regimen (N = 43) respectively. The end points of this study were response rate, survival, and toxicity. The overall response rates for DOF and ECF were 42·2% and 37·3%, and the respective tumour control rates were 80% and 60·6%, respectively. While the median progression-free survival (PFS) approached 6·7 and 5·0 months for DOF and ECF, the overall survival (OS) was 11·4 and 9·8 months respectively. Although both groups showed acceptable level of toxicity, compared with ECF, DOF group was associated with less nausea/vomiting and alopecia but more peripheral neuropathy and neutropenia. Although DOF and ECF exhibit similar efficacy, DOF may broaden the spectrum of chemotherapeutically treatable patients and deserve further investigation.

show abstract

A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Cited by 5 publications

References 29 publications

A clinical analysis of systemic chemotherapy combined with radiotherapy for advanced gastric cancer

A clinical analysis of systemic chemotherapy combined with radiotherapy for advanced gastric cancer

A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02

Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer

Contact Info

Product

Resources

About